Startups claim embryo screening can extend to IQ, sparking scepticism
The Economist reports on emerging claims from startups that go beyond standard medical screening, though the assertions have not convinced all observers.
A group of startups is asserting that they possess the capability to screen embryos for a broad spectrum of traits, extending well beyond the established testing for genetic diseases. According to reporting by The Economist, these firms claim they can now assess intelligence quotient (IQ) in embryos, a development that pushes the boundaries of current biotechnology applications.
The claims suggest a shift in the commercial landscape of reproductive technology, moving from solely preventing hereditary conditions to potentially selecting for cognitive traits. The reporting highlights the provocative nature of this potential market, framing the issue around the question of what consumers might be willing to pay for enhanced intelligence in offspring.
However, these assertions have not been universally accepted. The source material notes that not everyone is convinced by the startups' claims, indicating a significant degree of scepticism surrounding the feasibility and accuracy of such screening methods. It remains unclear whether this doubt stems from scientific limitations, ethical concerns, or market hesitation.
The specific entities making these claims have not been identified in the available reporting. Furthermore, there is no independent verification provided regarding the technical accuracy or reliability of IQ screening in embryos. The technology remains in the realm of startup claims rather than established, verified practice.
This development sits against the backdrop of embryo screening for genetic diseases, which is already an established area of biotechnology. The extension of these capabilities to non-medical traits like IQ introduces complex ethical and regulatory considerations that are yet to be fully addressed by policymakers or the scientific community.
